Recital 34, Regulation (EU) 2026/2348

In force

Three applications for the renewal of the approval of the active substance metamitron were submitted on 24, 25 and 29 August 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 September, and on 10 and 11 October 2016, respectively, that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) No 844/2012 and estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of February 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 32 months, until 31 July 2029.

  • celex=32012R0844